MENUMENU
  • Covid Clear
  • About Us
        • About Us

          An industry leading services provider in viral challenge studies and laboratory services supporting product development for customers developing antivirals, vaccines and respiratory therapeutics.

          • More about hVIVO
        • Overview
        • Executive Leadership Team
        • Scientific Papers / Abstracts
        • Quality Commitment
        • Ethics & Compliance
        • FluCamp
        • Human Challenge Programme
        • Challenge Agent Manufacturing
        • PrEP Biopharm Ltd
        • Imutex Ltd.
  • Services
        • Human challenge full-service solution
        • human challenge full service solution

          Industry leading provider of viral challenge studies

          • See Our Solution
        • hVIVO Challenge Models
          • Influenza
          • RSV
          • HRV
          • Asthma
          • COPD
          • Cough
        • Laboratory Services
          • Virology
          • Immunology
          • Biomarkers
  • News, Media & Events
        • News, Media & Events

          A source for the latest press releases, scientific publications and other media as well as details of investor and scientific events that we attend and host across the world.

        • News & Media
        • Media Coverage
        • Company News
        • Media Press Kit
        • Videos
        • Events
        • img

          LATEST PRESS RELEASE

          17.02.21 Ethics approval – COVID-19 Human Challenge Study
        • UPCOMING EVENTS

          Proactive Investors One2One Investor Forum

          Thursday 11th March

  • Volunteers
  • Careers
  • Contact Us

Tags

  • asthma & COPD
  • hrv
  • influenza
  • rsv

Scientific Papers / Abstracts: rsv

Scientific Paper 98 : Longitudinal analysis of leukocyte differentials in peripheral blood of patients with acute respiratory viral infections.

Scientific Paper 108 : Use of qualitative integrative cycler PCR (qicPCR) to identify optimal therapeutic dosing time-points in a Respiratory Syncytial Virus Human Viral Challenge Model (hVCM)

Scientific Paper 90 : Viral load drives disease in humans experimentally infected with respiratory syncytial virus

Scientific Paper 102 : Oral GS-5806 activity in a respiratory syncytial virus challenge study.

Scientific Paper 107 : Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.

Scientific Paper 89 : A randomised, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.

« Previous 1 2

Whether you’re a potential customer, job seeker, health professional or an investor, you can find the best way to contact us from the list below.

Contact Us
  • Terms & Conditions
  • Careers
  • Sitemap
© 2021 Copyright hVIVO Services Limited. All rights reserved. hVIVO Services Limited (“hVIVO”) is registered in England and Wales with registration number 02326557 and registered office at Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2AX, UK.
Privacy Policy | Cookie Policy